Part B Average Sales Price Drug Rates Finalized; Zoladex Down 12%
AstraZeneca's prostate cancer therapy Zoladex will be reimbursed at 12% below CMS' previously estimated rate when payment changes for Medicare Part B-covered drugs take effect Jan. 1
AstraZeneca's prostate cancer therapy Zoladex will be reimbursed at 12% below CMS' previously estimated rate when payment changes for Medicare Part B-covered drugs take effect Jan. 1